| Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. | |
| | |
MedLine Citation:
|
PMID: 14675099 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Plasmin is a direct thrombolytic which has been shown to have a strikingly favorable benefit to risk profile in comparison with plasminogen activators, notably tissue plasminogen activator (t-PA). As heparin is known to increase the risk of hemorrhage when co-administered with a plasminogen activator, we asked whether adjunct antithrombotic agents such as aspirin and heparin would affect the safety of plasmin. Three groups of rabbits were administered plasmin at a dose (4 mg kg-1) designed to induce significant decreases in antiplasmin, fibrinogen and factor (F)VIII, to about 25, 40 and 40%, respectively, of baseline values, but not cause prolongation of the ear puncture bleeding time. In a blinded and randomized trial, the results show that an intravenous aspirin bolus plus heparin administered as a bolus followed by a maintenance continuous infusion did not significantly prolong the bleeding time during plasmin infusion. These data indicate that in the rabbit, concomitant use of aspirin plus heparin does not affect the safety of a therapeutic dose of plasmin. |
| | |
Authors:
|
S Sadeghi; V J Marder; D Stewart; M Kong; J Humphries; G A Baumbach; G Jesmok |
Related Documents
:
|
19530909 - Effect of low-level laser therapy in the myonecrosis induced by bothrops jararacussu sn... 11251329 - Intestinal absorption of low molecular weight heparin in animals and human subjects. 8950779 - Antagonism of sr 90107a/org 31540-induced bleeding by protamine sulfate in rats and mice. 8191399 - Low affinity heparin is an antithrombotic agent. 9112669 - Interaction between the sulfated lactobionic acid (lw 10082) and other antithrombotic a... 6195759 - Phospholipase a activation following extracorporeal circulation and its blockade by pro... 1642909 - Extradural clonidine infusions for analgesia after total hip replacement. 21182429 - Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined ... 20697929 - In vitro degradation of zearalenone by bacillus subtilis. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of thrombosis and haemostasis : JTH Volume: 1 ISSN: 1538-7933 ISO Abbreviation: J. Thromb. Haemost. Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2003-12-16 Completed Date: 2004-02-20 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 101170508 Medline TA: J Thromb Haemost Country: England |
Other Details:
|
Languages: eng Pagination: 2621-5 Citation Subset: IM |
Affiliation:
|
Vascular Medicine Program, Los Angeles Orthopedic Hospital, and David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90007, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Aspirin / administration & dosage, adverse effects Bleeding Time Drug Interactions Drug Therapy, Combination Fibrinolysin / administration & dosage, adverse effects Fibrinolytic Agents / administration & dosage*, adverse effects* Hemorrhage / chemically induced* Heparin / administration & dosage, adverse effects Models, Animal Rabbits Thrombolytic Therapy / adverse effects |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 50-78-2/Aspirin; 9005-49-6/Heparin; EC 3.4.21.7/Fibrinolysin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by su...
Next Document: Potentiation of platelet activation through the stimulation of P2X1 receptors.